Arctic Bioscience AS · OSL:ABS

Arctic Bioscience AS — Q3 2026 Earnings Presentation

32 slides from Arctic Bioscience AS's earnings presentation, Nov 11, 2026

  1. Slide 1: Arctic Bioscience Q3 2026 update

    Arctic Bioscience Pioneers in natural resolution of inflammation Presentation of financial results; Q3 2026 update November 11th 2026 Christer L. Valderhaug (CEO) Runhild Gammelsæter (Medical Director) Jone R. Slinning (CFO)

  2. Slide 2: Disclaimer

    Disclaimer Matters discussed in this correct, and their methodology ascertain from the information Presentation may constitute or may be forward-looking and published by that third party, no include forward-looking speculative. facts have been omitted that statements. Forward-looking would render th

  3. Slide 3: Developing and commercializing pharmaceutical and nutraceutical products

    Developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds, utilizing proprietary technology and methodology

  4. Slide 4: Agenda

    Agenda Operational highlights Operational review Nutra Operational review Pharma Q3-2026 consolidated Group financial review Business outlook Q&A

  5. Slide 5: Intro and Q3-2026 operational highlights

    Intro and Q3-2026 operational highlights 5

  6. Slide 6: 2026 Q3 highlights

    2026 Q3 highlights HRO350 inflammation data sharpen the path forward Phase III design, EMA scientific advice and partnership discussions are the next steps Nutra revenue +26% Americas revenue +101% B2B revenue +31% NOK 32.6m in the first nine months of 2026, NOK 14.9m in the first nine months, NOK 2

  7. Slide 7: Operational review Nutra

    Operational review Nutra 7

  8. Slide 8: Nutra growth continued in Q3

    Nutra growth continued in Q3 NINE MONTHS TO 30 SEPTEMBER 2026 THIRD QUARTER NOK 32.6m NOK 9.3m Approximately 7% growth +26% year on year Q3 2025 revenue: NOK 8.7m NOK 25.9m in the same period of 2025 Supplier delivery delays continued to affect revenue timing Growth moderated from 35.2% in H1. The o

  9. Slide 9: B2B drives growth and a larger share of sales

    B2B drives growth and a larger share of sales NUTRA REVENUE BY CHANNEL, NOK MILLION 35 +31% y/y 29,2 30 B2B revenue growth to NOK 29.2m 25 22,3 20 B2C revenue: NOK 3.4m 15 10 Down 5.8% year on year The B2C plan prioritises existing customers 5 3,6 3,4 and lower marketing spend 0 B2B B2C 9M 2025 9M 2

  10. Slide 10: Americas revenue doubled and leads the sales mix

    Americas revenue doubled and leads the sales mix NUTRA REVENUE BY REGION, NOK MILLION 18 +101% 16 14,9 Americas revenue reached NOK 14 14.9m, or 46% of Nutra sales 12 10 9,3 9,1 8 7,4 APAC grew 15% to NOK 4.4m 6 5,4 Europe was broadly stable 4,2 4,4 Norway declined 22% 3,8 4 2 0 Norway Europe Americ

  11. Slide 11: Bevimi customer story: ROMEGA in Uno Protect

    Bevimi customer story (US): ROMEGA® in Uno Protect OCTOBER 2026 DEVELOPMENT Up to US$2m A daily liquid brain- Bevimi selected for ARPA-H research health supplement funding containing ROMEGA® phospholipids 150 adults Planned 24-week randomized, double-blind, placebo-controlled study of early cognitiv

  12. Slide 12: Napiers customer story: Arctic Omega-3

    Napiers customer story: Arctic Omega-3 NAPIERS THE HERBALISTS (UK) Arctic Omega-3 Napiers offers Norwegian herring caviar oil in its Arctic Omega-3 supplement - containing ROMEGA® phospholipids. Launched Aug/Sept

  13. Slide 13: NeuroReserve customer story: second ROMEGA product

    NeuroReserve customer story: second ROMEGA® product US CUSTOMER REO3 NeuroReserve has launched its second ROMEGA®-based product, using ROMEGA®-30 Premium The US brand positions REO3 around phospholipid omega-3 DHA and EPA, with specialized pro-resolving mediators (SPMs)

  14. Slide 14: Genstory customer story: ROMEGA launches in South Korea

    Genstory customer story: ROMEGA® launches in South Korea REGIONAL PARTNER Genstory Partner for Singapore and South Korea Recent South Korean launch brings ROMEGA® to the Coupang marketplace Premium, Eye Premium and Skin Refine listed on the Korean marketplace

  15. Slide 15: Commercial, product and operational development priorities

    Commercial-, product- and operational development priorities International B2B Support recurring customers and further develop Commercial focus new US customers and APAC partner channels. Several new international Brand-launches upcoming Product portfolio Adapt product formulations and applications

  16. Slide 16: Operational review Pharma

    Operational review Pharma 16

  17. Slide 17: Pharmaceutical pipeline and overall status

    Pharmaceutical pipeline and overall status ABS302 HRO350 ABS403 Brain development in Mild to moderate Psoriasis Glaucoma extremely premature infants Status Status Status • Phase 2b study completed • Successful formulation of two liquid • Successful clinical pilot study • Significant results on syste

  18. Slide 18: HRO350

    HRO350 Mild-to-moderate psoriasis

  19. Slide 19: HRO350: Beyond topicals, before biologics

    HRO350: Beyond topicals, before biologics HRO350 is an investigational medicinal product currently with phase 2b data in mild-to-moderate psoriasis

  20. Slide 20: HeROPA data publication plan H2 2026

    HeROPA data publication plan H2 2026 Publication STATUS NOV DEC Published (peer-review) Herring roe PLs promote SPM biosynthesis in macrophages and a https://www.jlr.org/article/S0022-2275(26)00042- keratinocyte/fibroblast coculture as a model of psoriasis 8/fulltext Published (peer-review) Herring

  21. Slide 21: Timeline toward phase 3 and partnering

    Timeline toward phase 3 and partnering November 5–7 April 2027 7–10 June 2027 Estimated start Scientific Advice BIOEurope BIOInternational procedure Lyon Philadelphia Estimated duration: 2–3 months Publications will coincide with the Scientific Advice submission

  22. Slide 22: ABS403

    ABS403 Glaucoma

  23. Slide 23: Future Directions for ABS403

    Future Directions for ABS403: Bioavailable with anti-inflammatory properties ABS403 in the resolution of inflammation • Bioavailable phospholipid-based treatment • Crosses the blood-brain and blood-retinal barrier • in vitro data from human immune cells and lipid mediators Future development of ABS4

  24. Slide 24: ABS302

    ABS302 Extremely premature infants

  25. Slide 25: Extremely premature infants (ABS302)

    Extremely premature infants (ABS302) • Being developed with Smerud Medical Research International • European consortium established for pre-clinical studies (efficacy and toxicology) • Prenatal departments at Inserm (France), Giannina Gaslini Institute (Italy), Lund and Gøteborg Hospitals (Sweden) •

  26. Slide 26: Q3-2026 consolidated group financial review

    Q3-2026 consolidated group financial review 26

  27. Slide 27: Key financial figures

    Key financial figures SALES REVENUES GROSS MARGIN AVAILABLE LIQUIDITY 32,6 39,7% 7,5 32,6% 25,9 29,4% 5,2 21,6% 8,7 9,3 1,4 Q3-2025 Q3-2026 YTDQ3-25 YTDQ3-26 Q3-2025 Q3-2026 YTDQ3-25 YTDQ3-26 30.09.2025 31.12.2025 30.09.2026

  28. Slide 28: EBITDA results

    EBITDA results TNOK YTDQ3-26 YTDQ3-25 Strong 26 % year-on-year sales revenue growth • The American market +100 % growth compared to YTD Q3-25 Total revenue 34 824 28 385 • Delays in deliveries from sub-suppliers are still affecting timing of Sales rev enue 32 558 25 945 our sales revenues Other inco

  29. Slide 29: Business outlook

    Business outlook 29

  30. Slide 30: Customer launches support the Nutra growth outlook

    Customer launches support the Nutra growth outlook 01 COMMERCIAL SCALE 02 SUPPLY POSITION 03 PHARMA & CAPITAL GROW DIFFERENTIATE DE-RISK Robust order pipeline and Strategic positioning and product Additional HeROPA publications recurring customers support differentiation are becoming should expand v

  31. Slide 31: Arctic Bioscience

    ARCTIC Bioscience

  32. Slide 32: Contact

    Contact CEO - Christer L. Valderhaug: christer@arctic-bioscience.com CFO - Jone R. Slinning jone@arctic-bioscience.com Medical Director - Runhild Gammelsæter: runhild@arctic-bioscience.com Subscribe to news www.arctic-bioscience.com/investors/home

Arctic Bioscience — Q3 2026 Earnings Presentation on 6ix